https://cav22inhibitor.com/sto....ry-applying-criteria
To evaluate the impact independent of Healthcare-Associated Pneumonia (HCAP), a sensitivity analysis was carried out, omitting cases of Pseudomonas aeruginosa or MRSA pneumonia. Within the studied population of 3775 patients, 1154 individuals received macrolide-based treatment. The absence of macrolides in a particular group led to unfavorable long-term clinical performance, measured by 6-month outcomes (315, 363/1154) versus 395 (103
お気に入り
コメント
シェア
